Physician profile
Jason Flicker
NPI 1528039286
$2,990.02
in general payments reported to CMS, 2019-2025
27 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $227 · 2021: $433 · 2022: $452 · 2023: $363 · 2024: $528 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.16 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $602.56 | 2019-2025 | Simbrinza, Tryptyr, Clareon |
| Allergan, INC. | $367.00 | 2019-2022 | |
| Abbvie INC. | $172.83 | 2022-2025 | |
| Oyster Point Pharma, INC. | $168.93 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $153.16 | 2019-2023 | Tecnis Iol |
| Ocular Therapeutix, INC. | $146.41 | 2019-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $143.90 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $136.89 | 2019-2023 | Cequa |
| Amgen INC. | $123.69 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $111.88 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $106.65 | 2019-2023 | |
| Sight Sciences, INC. | $106.10 | 2021-2023 | Tearcare System |
| Horizon Therapeutics Plc | $103.09 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $72.74 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $62.43 | 2022-2024 | Oxervate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $58.51 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.38 | 2019-2021 | |
| Harrow Eye, LLC | $47.58 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $46.02 | 2019-2021 | |
| Shire North American Group INC | $42.56 | 2019 | |
| Biotissue Holdings INC. | $38.13 | 2020-2024 | |
| Thea Pharma INC. | $36.97 | 2024 | Iyuzeh |
| Rxsight INC | $27.54 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Genentech USA, INC. | $23.31 | 2023 | Vabysmo |
| Ivantis, INC | $20.40 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.19 | 2021 | |
| Optos, INC. | $6.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Flicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.